Cover image not available

Costing statement : Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years
Alternative Title Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 0000
Publication location London

Topics

Asthma in children :: Chemotherapy :: Great Britain :: Cost effectiveness
England

Catalogue Data

OBNB ID GBB586364
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 618.92238

ISBD

P1053 1 online resource (2 pages)
P1042 Includes bibliographical references.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence. Publication and catalogue information, links to buy online and reader comments.